Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.

Abstract: Chemical formulations for chemical products can be represented by digital formulation graphs for use in machine learning models. The digital formulation graphs can be input to graph-based algorithms such as graph neural networks to produce a feature vector, which is a denser description of the chemical product than the digital formulation graph. The feature vector can be input to a supervised machine learning model to predict one or more attribute values of the chemical product that would be produced by the formulation without actually having to go through the production process. The feature vector can be input to an unsupervised machine learning model trained to compare chemical products based on feature vectors of the chemical products. The unsupervised machine learning model can recommend a substitute chemical product based on the comparison.

Abstract: The present invention relates to airfoils having surface treatments to reduce trailing edge noise. The surface treatment is designed to reduce trailing edge noise by modifying the boundary layer turbulence as it approaches the trailing edge. The surface treatment accomplishes its function by breaking up spanwise-oriented turbulence approaching the trailing edge, thereby reducing the spanwise correlation lengthscales; deflecting the boundary layer turbulence away from the edge; and/or creating spanwise vortices or instability waves to reduce the turbulence-edge interaction.

Abstract: The present invention relates to airfoils having surface treatments to reduce trailing edge noise. The surface treatment is designed to reduce trailing edge noise by modifying the boundary layer turbulence as it approaches the trailing edge. The surface treatment accomplishes its function by breaking up spanwise-oriented turbulence approaching the trailing edge, thereby reducing the spanwise correlation lengthscales; deflecting the boundary layer turbulence away from the edge; and/or creating spanwise vortices or instability waves to reduce the turbulence-edge interaction.

Abstract: A vehicle having a first configuration for road use and a second configuration for air use, comprising: road wheels; a traction drive propulsion unit for driving road wheels when in contact with the ground; a thrust propulsion unit for driving a propeller to drive the vehicle through the air; and wherein, when the vehicle is configurable into any of: the first configuration, in which the traction drive propulsion unit is engaged to drive the road wheels on the ground, and the thrust propulsion unit is disengaged from the propeller; the second configuration, in which the traction drive propulsion unit is disengaged such that no drive is provided to the road wheels, and the thrust propulsion unit is engaged with the propeller to drive the vehicle thorough the air; or an intermediate configuration in which the traction drive propulsion unit is engaged to drive the road wheels on the ground, and the thrust propulsion unit is engaged with the propeller to drive the vehicle through the air.

Abstract: The present invention relates to airfoils having surface treatments to reduce trailing edge noise. The surface treatment is designed to reduce trailing edge noise by modifying the boundary layer turbulence as it approaches the trailing edge. The surface treatment accomplishes its function by breaking up spanwise-oriented turbulence approaching the trailing edge, thereby reducing the spanwise correlation lengthscales; deflecting the boundary layer turbulence away from the edge; and/or creating spanwise vortices or instability waves to reduce the turbulence-edge interaction.

Abstract: A bromination process includes contacting fly ash with liquid bromine to increase the mercury adsorbing ability of the fly ash. The resultant brominated fly ash can be used to adsorb mercury in a high temperature combustion gas.

Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used to purge an ex vivo hematopoietic stem cell culture of cancer cells for engraftment in a mammal by administering the composition to the ex vivo hematopoietic stem cell culture in an effective amount.

Abstract: The invention relates to methods and apparatus for movement animation of a user-controlled entity in a virtual environment. Entity tracking data is stored on a server in order to track movement of the entity in the virtual environment. A user may input a desired action for their entity via a client, which is transmitted from the client to the server. The server uses the received data to select an appropriate animation for the entity. The server then transmits data identifying the selected animation to the client, thus controlling animation of the entity on the client. By using animation data to simulate movement of the entity, along with keeping an accurate representation of the movement of the entity in the virtual environment, the server may control the entity accurately and therefore animation of the entity may be more realistic.

Abstract: A use of a composition comprising an SDF-1 peptide having the sequence KGVSLSYR is taught. The composition can be used in the manufacture of a medicament for the treatment of a blood cancer in a mammal by administering the medicament in a therapeutically effective amount.

Abstract: A bromination process includes contacting fly ash with liquid bromine to increase the mercury adsorbing ability of the fly ash. The resultant brominated fly ash can be used to adsorb mercury in a high temperature combustion gas.

Abstract: Compositions comprising a peptide consisting of an amino acid sequence derived from a P2G-substituted SDF-1 protein are taught. The amino acid sequence consists of a first sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif. The amino acid sequences may also consist of one or more optional components selected from the group consisting of a second sequence consisting of 8 to 17 amino acids from the N-terminal portion of the SDF-1 protein and having a conserved KGVS motif, wherein the second sequence is covalently joined to the first sequence with or without a linker; and, a third sequence consisting of LKWIQEYLEKALN, or conservative substitutions thereof, wherein the third sequence is covalently joined to the first sequence with the linker. Methods of increasing multiplication of hematopoietic cells and enhancing proliferation of hematopoietic cells during engraftment are also taught.

Abstract: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.

Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.

Abstract: In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.

Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment of multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.

Abstract: A support catheter that can puncture a heart septum with a guidewire without buckling and that can access difficult to reach arteries such as carotid or renal arteries from the aorta under difficult circumstances is provided. The support catheter comprises a catheter body having a proximal end, a distal end, and an interior wall surface defining a first lumen extending from the proximal end toward the distal end. A second lumen is disposed between the interior wall surface and an outer surface of the catheter body. A plurality of stiffening members is disposed around the second lumen, the plurality of stiffening members being engageable to selectively stiffen the catheter body. In another configuration, the catheter further comprises a second plurality of stiffening members disposed between the first lumen and the second lumen.

Abstract: In accordance with various aspects of the invention, CXCR4 antagonists may be used to treat hematopoietic cells, such as progenitor or stem cells, to promote the rate of cellular multiplication, self-renewal, proliferation or expansion. CXCR4 antagonists may be used therapeutically to stimulate hematopoietic stem/progenitor cell multiplication/self-renewal.

Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.

Abstract: The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments. CXCR4 antagonsits may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.